CALA earnings call for the period ending March 31, 2019.
News & Analysis: Calithera Biosciences
The tiny pharma stock received an upgrade from a prominent analyst.
You don't need a million bucks to have a winning portfolio.
How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.
An expanded collaboration with Bristol-Myers Squibb and an update on first-quarter 2017 financials had investors cheering.